Cargando…

Assessing the Risk of Contrast-Induced Nephropathy Using a Finger Stick Analysis in Recalls from Breast Screening: The CINFIBS Explorative Study

PURPOSE: To evaluate whether a handheld point-of-care (POC) device is able to predict and discriminate patients at potential risk of contrast-induced nephropathy (CIN) prior to iodine-based contrast media delivery. METHODS AND MATERIALS: Between December 2014 and June 2016, women undergoing contrast...

Descripción completa

Detalles Bibliográficos
Autores principales: Houben, I. P. L., van Berlo, C. J. L. Y., Bekers, O., Nijssen, E. C., Lobbes, M. B. I., Wildberger, J. E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612678/
https://www.ncbi.nlm.nih.gov/pubmed/29097928
http://dx.doi.org/10.1155/2017/5670384
_version_ 1783266105392889856
author Houben, I. P. L.
van Berlo, C. J. L. Y.
Bekers, O.
Nijssen, E. C.
Lobbes, M. B. I.
Wildberger, J. E.
author_facet Houben, I. P. L.
van Berlo, C. J. L. Y.
Bekers, O.
Nijssen, E. C.
Lobbes, M. B. I.
Wildberger, J. E.
author_sort Houben, I. P. L.
collection PubMed
description PURPOSE: To evaluate whether a handheld point-of-care (POC) device is able to predict and discriminate patients at potential risk of contrast-induced nephropathy (CIN) prior to iodine-based contrast media delivery. METHODS AND MATERIALS: Between December 2014 and June 2016, women undergoing contrast-enhanced spectral mammography (CESM) with an iodine-based contrast agent were asked to have their risk of CIN assessed by a dedicated POC device (StatSensor CREAT) and a risk factor questionnaire based on national guidelines. Prior to contrast injection, a venous blood sample was drawn to compare the results of POC with regular laboratory testing. RESULTS: A total of 351 patients were included; 344 were finally categorized as low risk patients by blood creatinine evaluation. Seven patients had a eGFR below 60 ml/min/1.73 m(2), necessitating additional preparation prior to contrast delivery. The POC device failed to categorize six out of seven patients (86%), leading to (at that stage) unwanted contrast administration. Two patients subsequently developed CIN after 2–5 days, which was self-limiting after 30 days. CONCLUSION: The POC device tested was not able to reliably assess impairment of renal function in our patient cohort undergoing CESM. Consequently, we still consider classic clinical laboratory testing preferable in patients at potential risk for developing CIN.
format Online
Article
Text
id pubmed-5612678
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-56126782017-09-28 Assessing the Risk of Contrast-Induced Nephropathy Using a Finger Stick Analysis in Recalls from Breast Screening: The CINFIBS Explorative Study Houben, I. P. L. van Berlo, C. J. L. Y. Bekers, O. Nijssen, E. C. Lobbes, M. B. I. Wildberger, J. E. Contrast Media Mol Imaging Research Article PURPOSE: To evaluate whether a handheld point-of-care (POC) device is able to predict and discriminate patients at potential risk of contrast-induced nephropathy (CIN) prior to iodine-based contrast media delivery. METHODS AND MATERIALS: Between December 2014 and June 2016, women undergoing contrast-enhanced spectral mammography (CESM) with an iodine-based contrast agent were asked to have their risk of CIN assessed by a dedicated POC device (StatSensor CREAT) and a risk factor questionnaire based on national guidelines. Prior to contrast injection, a venous blood sample was drawn to compare the results of POC with regular laboratory testing. RESULTS: A total of 351 patients were included; 344 were finally categorized as low risk patients by blood creatinine evaluation. Seven patients had a eGFR below 60 ml/min/1.73 m(2), necessitating additional preparation prior to contrast delivery. The POC device failed to categorize six out of seven patients (86%), leading to (at that stage) unwanted contrast administration. Two patients subsequently developed CIN after 2–5 days, which was self-limiting after 30 days. CONCLUSION: The POC device tested was not able to reliably assess impairment of renal function in our patient cohort undergoing CESM. Consequently, we still consider classic clinical laboratory testing preferable in patients at potential risk for developing CIN. Hindawi 2017-09-11 /pmc/articles/PMC5612678/ /pubmed/29097928 http://dx.doi.org/10.1155/2017/5670384 Text en Copyright © 2017 I. P. L. Houben et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Houben, I. P. L.
van Berlo, C. J. L. Y.
Bekers, O.
Nijssen, E. C.
Lobbes, M. B. I.
Wildberger, J. E.
Assessing the Risk of Contrast-Induced Nephropathy Using a Finger Stick Analysis in Recalls from Breast Screening: The CINFIBS Explorative Study
title Assessing the Risk of Contrast-Induced Nephropathy Using a Finger Stick Analysis in Recalls from Breast Screening: The CINFIBS Explorative Study
title_full Assessing the Risk of Contrast-Induced Nephropathy Using a Finger Stick Analysis in Recalls from Breast Screening: The CINFIBS Explorative Study
title_fullStr Assessing the Risk of Contrast-Induced Nephropathy Using a Finger Stick Analysis in Recalls from Breast Screening: The CINFIBS Explorative Study
title_full_unstemmed Assessing the Risk of Contrast-Induced Nephropathy Using a Finger Stick Analysis in Recalls from Breast Screening: The CINFIBS Explorative Study
title_short Assessing the Risk of Contrast-Induced Nephropathy Using a Finger Stick Analysis in Recalls from Breast Screening: The CINFIBS Explorative Study
title_sort assessing the risk of contrast-induced nephropathy using a finger stick analysis in recalls from breast screening: the cinfibs explorative study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5612678/
https://www.ncbi.nlm.nih.gov/pubmed/29097928
http://dx.doi.org/10.1155/2017/5670384
work_keys_str_mv AT houbenipl assessingtheriskofcontrastinducednephropathyusingafingerstickanalysisinrecallsfrombreastscreeningthecinfibsexplorativestudy
AT vanberlocjly assessingtheriskofcontrastinducednephropathyusingafingerstickanalysisinrecallsfrombreastscreeningthecinfibsexplorativestudy
AT bekerso assessingtheriskofcontrastinducednephropathyusingafingerstickanalysisinrecallsfrombreastscreeningthecinfibsexplorativestudy
AT nijssenec assessingtheriskofcontrastinducednephropathyusingafingerstickanalysisinrecallsfrombreastscreeningthecinfibsexplorativestudy
AT lobbesmbi assessingtheriskofcontrastinducednephropathyusingafingerstickanalysisinrecallsfrombreastscreeningthecinfibsexplorativestudy
AT wildbergerje assessingtheriskofcontrastinducednephropathyusingafingerstickanalysisinrecallsfrombreastscreeningthecinfibsexplorativestudy